Browse > Article

Study of the Drugs Prescribed on Alzheimer's Disease: from the Insurance Claims Data of Korea National Health Insurance Service  

Kim, Jungeun (Graduate School of Clinical Pharmacy, Sookmyung Women's University)
Lee, Jonghyuk (National Health Insurance Service)
Jeong, Ji Hoon (College of Medicine, Chung-Ang University)
Kang, Minku (College of Pharmacy, Woosuk University)
Bang, Joon Seok (Graduate School of Clinical Pharmacy, Sookmyung Women's University)
Publication Information
Korean Journal of Clinical Pharmacy / v.24, no.4, 2014 , pp. 255-264 More about this Journal
Abstract
Objective: The aims of this study are to investigate the total volume of prescribed medicines against Alzheimer's disease (AD) and the trends of usage by analyzing the claims-data from the Korea National Health Insurance Service. Method: The demographic and claims-data were included the major AD treating medicines such as donepezil, galantamine, rivastigmine and memantine, and analyzed during the period of 2010~2012. The assessing criteria were gender, age, habitation, types of medical institution, code of ingredients, outcomes of treatment, volume and amount of claims, and the numbers of patients with dementias. After trimming the data, it were analyzed by the market size, demographic traits, characteristics of medical service, characteristics of each anti-AD medicine, etc. Results: Among the chosen 4 medicines, donepezil had the top prescription volumes. Most prevalent prescribing preparations of donepezil were conventional types. However, among the non-conventional types, oro-dispersible formulation is the fast increasing one in both volume and growth rate. This specialized preparations to improve both toleration and adherence, tend to being prescribed generally at the tertiary medical institutions. While the younger patients with mild-to-moderate AD mostly treated by expensive medicines in resident at the tertiary hospitals, the rest older patients with severe AD have been treated non-expensive one at long-term care facilities. Conclusion: AD is a chronic illness therefore, long-term use of therapeutic medications are highly important. If an anti-AD treatment was applied steadily in the earlier stages, it would be achieved not only improving the quality of life of patient but also reducing the expenses in the medical and nursing cares. As the socioeconomical impacts of AD is expanding, healthcare professionals need to aware the importance of pharmacotherapy and to improve sociopolitical fundamentals.
Keywords
Alzheimer's disease; claims data; donepezil; galantamine; rivastigmine; memantine;
Citations & Related Records
연도 인용수 순위
  • Reference
1 http://kostat.go.kr/portal/korea/index.action (Accessed on April 27, 2014)
2 Annual Reports of Center for Treatment of Dementias in Korea. 2013
3 http://www.edementia.or.kr/main/mainStart (Accessed on May 1, 2014)
4 National Plan of Management for Dementia. Korea Ministry of Food and Drug Safety. 2012
5 Katzman R. Education and the prevalence of dementia and Alzheimer's disease among community dwelling elderly persons and their first relatives. Ann Neurol 1993;33:494-501.   DOI   ScienceOn
6 Clinical Therapeutic Guideline for Dementias. Korea Ministry of Food and Drug Safety, 2009
7 Statistical Data of Health Insurance in Korea (2010-2013). Health Insurance Review & Assessment Service in Korea.
8 Lee KS, Suh HS. Alzheimer's Disease: Clinical Trials and Future Perspectives. Korean J Psychopharmacol 2012;23 (4):131-5.
9 Lee DW. Evidence-Based Treatment of Alzheimer's Disease. J Korean Med Assoc 2009;52(4):417-25.   DOI   ScienceOn
10 NICE technology appraisal guidance 217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of NICE technology appraisal guidance 111). 2011
11 Geldmacher DS. Treatment Guidelines for Alzheimer's Disease: Redefining Perceptions in Primary Care. Prim Care Companion J Clin Psychiatry 2007;9(2):113-21.   DOI   ScienceOn
12 Farlow MR, Cummings JL. Effective Pharmacologic Management of Alzheimer's Disease. Am J Med 2007; 120;388-97.   DOI   ScienceOn
13 Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD005593. DOI: 10.1002/14651858.CD005593.
14 Winblad B, Grossberg G, Frlich L, et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007;69 (Suppl 1):S14S22.
15 Heo JH, Kim H, Bae HJ, et al. Trend in Treatment of Dementia by Benefit Cost Status based on Health Insurance Review & Assessment Service (HIRA)'s Data from 2003 to 2007. Dementia and Neurocognitive Disorders 2010;9:29-35.
16 Kim JM. Current problems and resolutions on the health policies for patients with dementias. Public Administration and Research 2006;7(2):133-50.
17 Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews 2006, Issue 1.
18 Tanna S. Background Paper 6.11 Alzheimer Disease and other Dementias. 2013
19 http://www.alz.org/ Alzheimer's Association of USA (Accessed on 5. 1. 2014)
20 National Plan of Management for Dementia. Korea Ministry of Food and Drug Safety. 2009.
21 Survey of the Prevalence of Dementia in Korea (2008). Ministry of Health and Welfare
22 BUSINESS WIRE. Research and Markets: Global Alzheimer Prevalence and Drugs Demand. April 12, 2011.
23 Notice #2013-127 of Korea Ministry of Health and Welfare September 1, 2013.
24 Castro DM. The economic cost of Alzheimer's disease family or public-health burden. Dement Neuropsychol 2010;4(4):262-7.   DOI
25 Overcome of the barriers in Dementias. News clipping of Medical Observer. Feb. 2014.